---

---

symbols : GSK   

save search

---

Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
Published: 2021-01-27 (Crawled : 12:00) - globenewswire.com
GSK | News | $40.755 -1.18% 660K |

Health Technology

| 5.1% | O: -1.12% H: 0.1% C: -1.6%
LLY | News | $731.81 -1.86% 1M |

Health Technology

| 247.43% | O: -0.78% H: 0.45% C: -1.66%
VIR | $8.145 0.19% 140K |

Health Technology

| -89.49% | O: -7.13% H: 96.21% C: 15.59%
covid ev biotech trial

---

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr
Published: 2022-09-22 (Crawled : 07:00) - biospace.com/
GSK | News | $40.755 -1.18% 660K |

Health Technology

| 38.53% | O: -0.71% H: 2.03% C: 1.52%
SPRO | $1.435 46K |

Health Technology

| 75.25% | O: 148.27% H: 55.88% C: 7.84%
license therapeutics agreement

---

Europe Frontotemporal Dementia Market Research Report 2023: Growing Prevalence of Dementia & Increasing Number of Clinical Trials - Competition, Forecasts & Opportunities to 2028
Published: 2023-04-26 (Crawled : 15:20) - prnewswire.com
GLAXF | News | $19.54 2.6K |

Health Technology

| 2.68% | O: -4.57% H: 0.22% C: -1.98%
SNYNF | News | $94.25 480 |

Health Technology

| -16.59% | O: -1.46% H: 0.0% C: 0.0%
NVSEF | News | $96.0 52K |

Health Technology

| 10.34% | O: 0.0% H: 0.0% C: 0.0%
VTRS | News A | $11.37 0.09% 1.2M |

Health Technology

| 23.75% | O: 0.22% H: 0.65% C: -1.09%
NVS | News | $97.755 0.49% 1.1M |

Health Technology

| -4.98% | O: 0.62% H: 0.0% C: -2.04%
JNJ | News | $148.22 -0.9% 3.3M |

Health Technology

| -9.4% | O: -0.66% H: 0.18% C: -0.9%
GSK | News | $40.755 -1.18% 660K |

Health Technology

| 11.73% | O: -0.03% H: 0.3% C: -2.63%
SNY | News | $46.615 -2.25% 730K |

Health Technology

| -18.13% | O: 0.53% H: 0.0% C: 0.0%
CNTG | $0.475 -1.04% 10K |

Commercial Services

| -70.55% | O: 1.23% H: 27.27% C: -15.76%
europe report dementia trials research growing market

---

Wave Life Sciences and GSK Announce Collaboration to Drive Discovery and Development of Oligonucleotide Therapeutics Focusing on Novel Genetic Targets
Published: 2022-12-13 (Crawled : 13:20) - biospace.com/
GSK | News | $40.755 -1.18% 660K |

Health Technology

| 15.49% | O: 2.3% H: 0.66% C: -1.04%
WVE | $5.1 0.39% 110K |

Health Technology

| 40.72% | O: 19.11% H: 18.37% C: 11.4%
sciences collaboration life genetic therapeutics

---

Fulcrum Therapeutics Announces Second Quarter 2022 Financial Results and Business Update
Published: 2022-08-11 (Crawled : 12:00) - biospace.com/
GLAXF | News | $19.54 2.6K |

Health Technology

| 2.63% | O: -12.81% H: 8.43% C: 5.21%
GSK | News | $40.755 -1.18% 660K |

Health Technology

| 7.68% | O: -8.67% H: 2.89% C: 2.14%
FULC | $7.29 -2.02% 66K |

Health Technology

| -4.12% | O: -10.82% H: 17.27% C: 9.39%
therapeutics update results

---

Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
Published: 2021-01-12 (Crawled : 08:03) - globenewswire.com
GSK | News | $40.755 -1.18% 660K |

Health Technology

| 8.73% | O: -0.29% H: 0.21% C: -0.95%
VIR | $8.145 0.19% 140K |

Health Technology

| -71.23% | O: 1.91% H: 16.28% C: 11.28%
covid biotech treatment

---

SpringWorks Announces Expansion of Global, Non-Exclusive Collaboration with GSK for Nirogacestat in Combination with Blenrep in Patients with Multiple Myeloma
Published: 2022-09-07 (Crawled : 14:00) - globenewswire.com
GSK | News | $40.755 -1.18% 660K |

Health Technology

| 31.05% | O: -0.83% H: 1.22% C: 0.9%
SWTX | $43.7 -0.68% 120K |

Health Technology

| 69.17% | O: -0.38% H: 15.79% C: 7.56%
expansion collaboration

---

Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
Published: 2023-04-11 (Crawled : 15:20) - biospace.com/
GSK | News | $40.755 -1.18% 660K |

Health Technology

| 8.9% | O: -0.11% H: 0.0% C: -1.27%
ADAP | $1.08 -5.26% 330K |

Health Technology

| 0.88% | O: -1.77% H: 11.71% C: 9.01%
transfer back

---

Anxious World Waits As Covid Vaccine Makers Address Omicron Variant
Published: 2021-12-07 (Crawled : 14:00) - prnewswire.com
GLAXF | News | $19.54 2.6K |

Health Technology

| -2.88% | O: 5.22% H: 0.0% C: -1.25%
JNJ | News | $148.22 -0.9% 3.3M |

Health Technology

| -6.73% | O: 2.13% H: 0.0% C: 0.0%
GSK | News | $40.755 -1.18% 660K |

Health Technology

| -1.5% | O: 0.14% H: 0.0% C: 0.0%
VIR | $8.145 0.19% 140K |

Health Technology

| -80.8% | O: -6.42% H: 8.6% C: 8.45%
SRNE | $0.015 56K |

Health Technology

| -99.8% | O: 6.57% H: 14.77% C: 11.21%
RDHL | $0.429 0.28% 150K |

Health Technology

| -84.01% | O: 0.37% H: 10.37% C: 9.63%
covid vaccine

---

Vir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
Published: 2021-03-03 (Crawled : 15:00) - biospace.com/
GSK | News | $40.755 -1.18% 660K |

Health Technology

| 20.97% | O: -0.26% H: 0.93% C: 0.71%
VIR | $8.145 0.19% 140K |

Health Technology

| -85.92% | O: -28.99% H: 8.39% C: 1.9%
covid biotech iot trial

---

Anti-obesity Drugs Market Size to Grow by USD 454.51 million | Growing Obese Population to Boost Market Growth | 17,000+ Technavio Research Reports
Published: 2022-07-06 (Crawled : 15:00) - prnewswire.com
GLAXF | News | $19.54 2.6K |

Health Technology

| -24.26% | O: -0.73% H: 1.02% C: 1.02%
GSK | News | $40.755 -1.18% 660K |

Health Technology

| -23.81% | O: -0.51% H: 0.73% C: 0.07%
BHC | $8.49 -0.47% 380K |

Health Technology

| -5.75% | O: -0.77% H: 1.61% C: -4.45%
RYTM A | $40.08 0.2% 160K |

Health Technology

| 809.09% | O: 0.45% H: 8.37% C: 7.24%
research growing growth market obesity

---

Zentalis Announces Preclinical Data Supporting Cyclin E1 As A Predictive Marker For Azenosertib Treatment At AACR Annual Meeting 2023
Published: 2023-04-17 (Crawled : 14:00) - biospace.com/
GLAXF | News | $19.54 2.6K |

Health Technology

| 4.77% | O: 0.88% H: 3.85% C: 3.85%
GSK | News | $40.755 -1.18% 660K |

Health Technology

| 9.19% | O: -0.24% H: 0.01% C: -0.77%
ZNTL | $12.06 -4.06% 140K |

Health Technology

| -31.09% | O: 1.54% H: 8.37% C: 5.89%
treatment preclinical meeting

---

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-03-17 (Crawled : 12:00) - biospace.com/
GLAXF | News | $19.54 2.6K |

Health Technology

| -9.07% | O: -1.77% H: 0.0% C: -3.55%
CGEM | $18.42 10.5% 220K |

| 36.08% | O: -2.53% H: 7.62% C: 7.29%
GSK | News | $40.755 -1.18% 660K |

Health Technology

| -1.5% | O: 0.6% H: 2.92% C: 2.21%
financial results report results

---

New Data for AREXVY, GSK’s RSV Vaccine, Show Potential to Help Protect Adults Aged 50 to 59 at Increased Risk for RSV Disease
Published: 2023-10-25 (Crawled : 12:00) - biospace.com/
GSK | News | $40.755 -1.18% 660K |

Health Technology

| 14.62% | O: 0.42% H: 0.43% C: -0.22%
AGEN A | $6.94 7.43% 660K |

Health Technology

| 756.08% | O: -0.12% H: 7.47% C: 3.21%
disease risk rsv potential show

---

Cellular Immunotherapy Market Research Report by Type, Indication, Technology Type, End Use, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-11-10 (Crawled : 17:00) - prnewswire.com
GLAXF | News | $19.54 2.6K |

Health Technology

| 25.66% | O: -0.06% H: 0.0% C: 0.0%
AZNCF | News | $140.3 1.5K |

Health Technology

| 16.43% | O: 6.22% H: 3.13% C: -0.56%
NVS | News | $97.755 0.49% 1.1M |

Health Technology

| 19.15% | O: 2.81% H: 0.43% C: -0.2%
JNJ | News | $148.22 -0.9% 3.3M |

Health Technology

| -14.06% | O: 0.18% H: 0.0% C: 0.0%
GSK | News | $40.755 -1.18% 660K |

Health Technology

| 27.21% | O: 2.59% H: 0.72% C: 0.63%
BMY | $48.76 -0.47% 3.9M |

Health Technology

| -38.59% | O: 1.22% H: 0.01% C: -1.7%
IOVA M | $11.785 -0.63% 1.5M |

Health Technology

| 51.28% | O: 6.12% H: 4.99% C: 4.21%
INO | $10.185 -1.78% 110K |

Health Technology

| 375.69% | O: 5.5% H: 4.35% C: 3.48%
GILD | $67.03 2.4M |

Health Technology

| -18.57% | O: 1.43% H: 0.36% C: -1.08%
ATRA | $0.7202 0.22% 210K |

Health Technology

| -81.44% | O: 2.58% H: 23.12% C: 20.85%
AZN | News | $71.065 0.3% 3.2M |

Health Technology

| 16.05% | O: 7.08% H: 0.84% C: -0.43%
ADAP | $1.08 -5.26% 330K |

Health Technology

| -45.71% | O: 0.0% H: 7.14% C: 5.71%
covid-19 research global immunotherapy report impact technology market

---

US FDA Approves GSK’s AREXVY, the World’s First Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
Published: 2023-05-03 (Crawled : 23:00) - biospace.com/
GSK | News | $40.755 -1.18% 660K |

Health Technology

| 13.45% | O: 1.24% H: 1.14% C: 0.11%
AGEN A | $6.94 7.43% 660K |

Health Technology

| 358.16% | O: 1.42% H: 6.99% C: 4.2%
fda vaccine respiratory virus

---

GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies
Published: 2023-08-17 (Crawled : 18:00) - biospace.com/
GSK | News | $40.755 -1.18% 660K |

Health Technology

| 17.66% | O: -0.83% H: 0.62% C: 0.29%
AGEN A | $6.94 7.43% 660K |

Health Technology

| 412.7% | O: 0.0% H: 6.35% C: 4.76%
retail respiratory virus

---

Global Lupus Therapeutic Market to Surpass US$ 5,408.1 Million by 2030, Says Coherent Market Insights
Published: 2022-03-16 (Crawled : 18:00) - prnewswire.com
GLAXF | News | $19.54 2.6K |

Health Technology

| -6.33% | O: -0.46% H: 3.49% C: 3.49%
NVSEF | News | $96.0 52K |

Health Technology

| 18.23% | O: 2.25% H: 0.0% C: 0.0%
UCBJY | $65.26 5.9K |

Manufacturing

| 18.29% | O: 1.41% H: 2.33% C: 0.04%
TAK | News | $13.215 -1.23% 410K |

Health Technology

| -7.9% | O: 2.07% H: 1.62% C: 1.56%
NVS | News | $97.755 0.49% 1.1M |

Health Technology

| 17.36% | O: 0.74% H: 0.0% C: 0.0%
GSK | News | $40.755 -1.18% 660K |

Health Technology

| -1.1% | O: 0.41% H: 0.0% C: 0.0%
BMY | $48.76 -0.47% 3.9M |

Health Technology

| -29.76% | O: 0.26% H: 0.31% C: -0.39%
SNY | News | $46.615 -2.25% 730K |

Health Technology

| -8.51% | O: 0.82% H: 0.0% C: 0.0%
AUPH | $5.01 -1.57% 450K |

Health Technology

| -51.48% | O: 0.95% H: 6.23% C: 5.19%
AMGN | News | $274.065 0.19% 570K |

Health Technology

| 18.13% | O: 0.41% H: 0.0% C: -0.37%
lupus market

---

$12+ Billion Influenza Vaccines Market to Grow at 7+% CAGR, Globally, by 2028 Lead by Quadrivalent Vaccines Segment with 88.36% Market Share in 2022 | The Insight Partners
Published: 2022-10-28 (Crawled : 11:00) - prnewswire.com
SNYNF | News | $94.25 480 |

Health Technology

| 12.94% | O: 3.33% H: 0.74% C: -1.67%
GSK | News | $40.755 -1.18% 660K |

Health Technology

| 26.04% | O: 0.89% H: 1.3% C: 0.79%
SNY | News | $46.615 -2.25% 730K |

Health Technology

| 12.64% | O: 2.57% H: 0.0% C: 0.0%
MRNA | News S | $107.135 -0.7% 2.1M |

Health Technology

| -25.13% | O: -0.88% H: 5.85% C: 5.69%
influenza market vaccine

---

ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President of Translational Sciences and Preclinical Development
Published: 2021-06-17 (Crawled : 12:00) - globenewswire.com
GSK | News | $40.755 -1.18% 660K |

Health Technology

| 1.43% | O: -0.47% H: 0.44% C: 0.25%
CFRX | $0.05 0.0% 910K |

Health Technology

| -98.8% | O: 0.24% H: 5.29% C: -1.2%
preclinical pre-clinical

---

Gainers vs Losers

54%

46%

Top 10 Gainers

CSSE 4 | $0.3499 129.74% 150M |

Consumer Services

CZOO | $11.04 121.24% 9.6M |

BOF | $2.05 75.21% 78M |

AMST | $3.2 60.0% 63M |

Technology Services

LICN | $0.8592 53.43% 13M |

WIMI | $1.05 44.75% 13M |

Technology Services

TROO | $1.51 38.53% 5.6M |

Manufacturing

MULN | News | $3.675 34.62% 11M |

Information

RILY | $28.605 31.7% 9.9M |

Finance

RBBN 4 | $3.305 28.6% 1.9M |

Electronic Technology

---

Your saved searches

---